SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it has introduced a flexible, high-throughput DNA methylation profiling technology capable of surveying up to 1,536 methylation sites across 96 samples simultaneously. By pairing Illumina’s proven BeadArray platform with the GoldenGate® assay approach, researchers have the ability to perform genome-wide methylation profiling across multiple areas such as cancer and human embryonic stem cell research. The GoldenGate Methylation Cancer Panel I, the first standard panel, covers 1,505 methylation sites over 800 cancer genes. Custom-content methylation panels will soon be available to meet individual research needs.
